In summary, immunotherapy combined with anti-angiogenetic agents holds promise as a superior therapeutic strategy in patients diagnosed with BCLC C stage, ECOG 1, EHS, AFP levels<400ng/ml, and viral hepatitis positivity, particularly HBV. This evidence concerns the gene AFP and viral hepatitis.